

INFECTED BLOOD INQUIRY

BRENDON GRAY WITNESS STATEMENT

EXHIBIT WITN6984137

HEPATITIS
DANGER
SEE
INSERT
LEAFLET

INSTRUCTION — RECONSTITUTION

1. Allow to warm to 20-30°C before reconstitution.
2. Transfer 10 mL of diluent to the bottle of lyophilised Koate®-HT.
3. After the diluent has been added, gently swirl the mixture until the powder is completely dissolved. Avoid foaming.
4. Withdraw the Koate®-HT solution through the filter needle which is enclosed.
5. Do not refrigerate after reconstitution.
6. Administer within three hours after reconstitution.
7. If a gel forms on reconstitution, do not use.
8. See Insert Leaflet for detailed instructions.

Antihaemophilic Factor (Human), Heat-Treated Dried Factor VIII Fraction Heat-Treated — Koate®-HT Lyophilised Powder



**Directions For Use: See Insert Leaflet.
Store at 2-8°C. DO NOT FREEZE.**

CONTENTS: One bottle of Koate®-HT
10 mL Sterile Water for Injection
One sterile filter needle
One sterile double-ended transfer needle

**Contains no preservative
For intravenous administration only
Sterile — Nonpyrogenic**

U.S. License No. B
Product License No. 0055/0107

Code
655-20E

Mfd. by **Cutter Biological**
Berkeley, CA 94710 USA, Division of
Miles Laboratories, Inc., Elkhart, IN 46514 USA
Dist. by **Cutter** Division of Miles Laboratories, Ltd.
Stoke Court, Stoke Poges, Slough SL2 4LY England

Coburn
Co., Inc.



Open Other End

Date removed
from refrigerator
**POSSIBLE
DON'T USE**

**Antihaemophilic
Factor (Human)
Dried Factor VIII
Fraction, Heat-Treated
Koate®-HT
Lyophilised Powder**

Mfd. by **Cutter Biological**
Berkeley, CA 94710 USA, Division of
Miles Laboratories, Inc., Elkhart, IN 46514 USA
Dist. by **Cutter** Division of Miles Laboratories, Ltd.
Stoke Court, Stoke Poges, Slough SL2 4LY England

Date removed
from refrigerator

**Antihaemophilic
Factor (Human)
Dried Factor VIII
Fraction, Heat-Treated
Koate®-HT
Lyophilised Powder**

Mfd. by **Cutter Biological**
Berkeley, CA 94710 USA, Division of
Miles Laboratories, Inc., Elkhart, IN 46514 USA
Dist. by **Cutter** Division of Miles Laboratories, Ltd.
Stoke Court, Stoke Poges, Slough SL2 4LY England

66-0655-203E
66-0655-203E
66-0655-203E
66-0655-203BE

Cutter

POM

Electrolyte Concentration
Cations Not more than 55 mMOL
Sodium Not more than 200 mMOL
Chloride Not more than 200 mMOL
Fibrinogen Not more than 80% of protein



Code
655-20E

Antihemophilic Factor
(Human), Heat-Treated
Dried Factor VIII Fraction
Heat-Treated — Koate[®]-H1

WARNING: THIS PRODUCT IS PREPARED FROM LARGE POOLS OF HUMAN PLASMA WHICH MAY CONTAIN THE CAUSATIVE AGENTS OF NON-A, NON-B HEPATITIS, HEPATITIS B AND OTHER VIRAL DISEASES. EACH UNIT OF PLASMA HAS BEEN TESTED AND FOUND NONREACTIVE FOR HBsAg AND HTLV-III ANTIBODY BY FDA APPROVED TESTS. THE PRESENCE OF HEPATITIS VIRUSES SHOULD BE ASSUMED AND THE HAZARD OF ADMINISTERING THIS PRODUCT SHOULD BE WEIGHED AGAINST THE MEDICAL CONSEQUENCES OF WITH-HOLDING TREATMENT. SEE PACKAGE INSERT WARNINGS.

Reconstitute with 10 mL Sterile Water for Injection.

Contains glycine

Not Returnable for Credit or Exchange

MILES

For Intravenous Administration Only
 Contains No Preservative
 Sterile — Nonpyrogenic
 To be diluted with 20 mL Sterile Water for Injection
 HEPATITIS DANGER — SEE INSERT LEAFLET
 For the use of this product, see insert leaflet.
 Store at 2-8°C. DO NOT FREEZE.
 Allow to warm to 20-30°C before
 reconstitution.
 If a gel forms on reconstitution, do not use.
 Contains No Preservative
 Sterile — Nonpyrogenic
 To be diluted with 20 mL Sterile Water for Injection
 HEPATITIS DANGER — SEE INSERT LEAFLET
 For the use of this product, see insert leaflet.
 Store at 2-8°C. DO NOT FREEZE.
 Allow to warm to 20-30°C before
 reconstitution.
 If a gel forms on reconstitution, do not use.
 Contains No Preservative
 Sterile — Nonpyrogenic
 To be diluted with 20 mL Sterile Water for Injection
 HEPATITIS DANGER — SEE INSERT LEAFLET
 For the use of this product, see insert leaflet.
 Store at 2-8°C. DO NOT FREEZE.
 Allow to warm to 20-30°C before
 reconstitution.
 If a gel forms on reconstitution, do not use.

Antihaemophilic Factor (Human), Heat-Treated Dried Factor VIII Fraction, Heat-Treated Koate®-HT Lyophilised Powder
 U.S. License No. 8 0055/0107
 Product License No. 0055/0107
 Mfd. by Cutter Biological
 Berkeley, CA 94710 USA, Division of
 Miles Laboratories, Inc., Elkhart, IN 46514 USA
 Dist. by Cutter Division of Miles Laboratories, Ltd.
 Stoke Court, Stoke Poges, Slough SL2 4LY England

For Intravenous Administration Only
 Contains No Preservative
 Sterile — Nonpyrogenic
 To be diluted with 20 mL Sterile Water for Injection
 HEPATITIS DANGER — SEE INSERT LEAFLET
 For the use of this product, see insert leaflet.
 Store at 2-8°C. DO NOT FREEZE.
 Allow to warm to 20-30°C before
 reconstitution.
 If a gel forms on reconstitution, do not use.
 Contains No Preservative
 Sterile — Nonpyrogenic
 To be diluted with 20 mL Sterile Water for Injection
 HEPATITIS DANGER — SEE INSERT LEAFLET
 For the use of this product, see insert leaflet.
 Store at 2-8°C. DO NOT FREEZE.
 Allow to warm to 20-30°C before
 reconstitution.
 If a gel forms on reconstitution, do not use.

Antihaemophilic Factor (Human), Heat-Treated Dried Factor VIII Fraction, Heat-Treated Koate®-HT Lyophilised Powder
 U.S. License No. 8 0055/0107
 Product License No. 0055/0107
 Mfd. by Cutter Biological
 Berkeley, CA 94710 USA, Division of
 Miles Laboratories, Inc., Elkhart, IN 46514 USA
 Dist. by Cutter Division of Miles Laboratories, Ltd.
 Stoke Court, Stoke Poges, Slough SL2 4LY England

HEPATITIS
 DANGER
 SEE
 INSERT
 LEAFLET

INSTRUCTION — RECONSTITUTION

1. Allow to warm to 20-30°C before reconstitution.
2. Transfer 20 mL of diluent to the bottle of lyophilised Koate®-HT.
3. After the diluent has been added, gently swirl the mixture until the powder is completely dissolved. Avoid foaming.
4. Withdraw the Koate®-HT solution through the filter needle which is enclosed.
5. Do not refrigerate after reconstitution.
6. Administer within three hours after reconstitution.
7. If a gel forms on reconstitution, do not use.
8. See Insert Leaflet for detailed instructions.

Antihaemophilic Factor (Human), Heat-Treated Dried Factor VIII Fraction Heat-Treated — Koate®-HT Lyophilised Powder

Directions For Use: See Insert Leaflet.
Store at 2-8°C. DO NOT FREEZE.
CONTENTS: One bottle of Koate®-HT
 20 mL Sterile Water for Injection
 One sterile filter needle
 One sterile double-ended transfer needle
Contains no preservative
For intravenous administration only
Sterile — Nonpyrogenic
 U.S. License No. 8
 Product License No. 0055/0107

Code
 655-30E

Mfd. by Cutter Biological
 Berkeley, CA 94710 USA, Division of
 Miles Laboratories, Inc., Elkhart, IN 46514 USA
 Dist. by Cutter Division of Miles Laboratories, Ltd.
 Stoke Court, Stoke Poges, Slough SL2 4LY England

Marville
 60



Open Other End



66-0655-303E
 66-0655-302E
 66-0655-302HE
 66-0655-303BE



POM

Electrolyte Concentration
 Citrate Not more than 55 mmol/L
 Sodium Not more than 200 mmol/L
 Chloride Not more than 300 mmol/L
 Fibrinogen Not more than 80% of protein



Code
 655-30E

Antihemophilic Factor
 (Human), Heat-Treated
 Dried Factor VIII Fraction
 Heat-Treated — Kocate-HT

Batch No.
 Expiry Date
 Grant/Printed name
 Lot/Vial
 Date received
 from reference

WARNING: THIS PRODUCT IS PREPARED FROM LARGE POOLS OF HUMAN PLASMA WHICH MAY CONTAIN THE CAUSATIVE AGENTS OF NON-A, NON-B HEPATITIS, HEPATITIS B AND OTHER VIRAL DISEASES. EACH UNIT OF PLASMA HAS BEEN TESTED AND FOUND NONREACTIVE FOR HBsAg AND HTLV-III ANTIBODY BY FDA APPROVED TESTS. THE PRESENCE OF HEPATITIS VIRUSES SHOULD BE ASSUMED AND THE HAZARD OF ADMINISTERING THIS PRODUCT SHOULD BE WEIGHED AGAINST THE MEDICAL CONSEQUENCES OF WITHHOLDING TREATMENT. SEE PACKAGE INSERT WARNINGS.

Reconstitute with 20 mL Sterile Water for Injection.

Contains glycine

Not Returnable for Credit or Exchange

MILES

65-0655-503E
65-0655-502E
65-0655-502HE
65-0655-503BE

Cutter

Cutter

**Antihæmophilic Factor
(Human), Heat-Treated
Dried Factor VIII Fraction
Heat-Treated — Koate®-HT
Lyophilised Powder**

**Directions For Use: See Insert Leaflet.
Store at 2-8°C. DO NOT FREEZE.**

CONTENTS: One bottle of Koate®-HT
40 mL Sterile Water for Injection
One sterile filter needle
One sterile double-ended transfer needle

**Contains no preservative
For intravenous administration only
Sterile — Nonpyrogenic**


U.S. License No. 8
Product License No. 0055/0107

POM


Code
655-50E

Electrolyte Concentration	
Citrate	Not more than 55 mMol/L
Sodium	Not more than 200 mMol/L
Chloride	Not more than 200 mMol/L
Fibrinogen	Not more than 80% of protein

Mfd. by **Cutter Biological**
Berkeley, CA 94710 USA, Division of
Miles Laboratories, Inc., Elkhart, IN 46514 USA
Dist. by **Cutter** Division of Miles Laboratories, Ltd.
Stoke Court, Stoke Poges, Slough SL2 4LY England



Open Other End





DATE REMOVED
FROM REFRIGERATOR
EXPIRY DATE
1.0 / VIAL
GRAMS PROTEIN PER VIAL
BATCH NO.

Antihaemophilic Factor
(Human), Heat-Treated
Dried Factor VIII Fraction
Heat-Treated — Koate®-HT
Code
655-50E

HEPATITIS
DANGER
SEE
INSERT
LEAFLET

WARNING: THIS PRODUCT IS PREPARED FROM LARGE POOLS OF HUMAN PLASMA WHICH MAY CONTAIN THE CAUSATIVE AGENTS OF NON-A, NON-B HEPATITIS, HEPATITIS B AND OTHER VIRAL DISEASES. EACH UNIT OF PLASMA HAS BEEN TESTED AND FOUND NON-REACTIVE FOR HBsAg AND HTLV-III ANTIBODY BY FDA APPROVED TESTS. THE PRESENCE OF HEPATITIS VIRUSES SHOULD BE ASSUMED AND THE HAZARD OF ADMINISTERING THIS PRODUCT SHOULD BE WEIGHED AGAINST THE MEDICAL CONSEQUENCES OF WITHHOLDING TREATMENT. SEE PACKAGE INSERT WARNINGS.

Reconstitute with 40 mL Sterile Water for Injection.

Contains glycine

Not Returnable for Credit or Exchange

**INSTRUCTION —
RECONSTITUTION**

1. Allow to warm to 20-30°C before reconstitution.
2. Transfer 40 mL of diluent to the bottle of lyophilised Koate®-HT.
3. After the diluent has been added, gently swirl the mixture until the powder is completely dissolved. Avoid foaming.
4. Withdraw the Koate®-HT solution through the filter needle which is enclosed.
5. Do not refrigerate after reconstitution.
6. Administer within three hours after reconstitution.
7. If a gel forms on reconstitution, do not use.
8. See Insert Leaflet for detailed instructions.

MILES

Colonial
Eastern
Co., Inc.

FACSIMILE
DON'T USE

**Antihæmophilic
Factor (Human)
Heat-Treated
Dried Factor VIII
Fraction, Heat-Treated
Kofate[®]-HT
Lyophilised Powder**

U.S. License No. 8
Product License No. 0055/0107

Mfd. by **Cutter Biologicals**
Berkeley, CA 94710 USA, Division of
Miles Laboratories, Inc., Elkhart, IN 48514 USA
Dist. by **Cutter** Division of Miles Laboratories, Ltd.
Stoke Court, Stoke Poges, Slough SL2 4LY England

Date removed
from refrigerator _____

For Intravenous Administration Only
Contains No Preservative
Sterile — Nonpyrogenic
To be diluted with 40 ml. Sterile Water for Injection
HEPATITIS DANGER — SEE INSERT LEAFLET
The risk of transmission of hepatitis is present.
Directions For Use: See Insert Leaflet.
Store at 2-8°C. DO NOT FREEZE.
Allow to warm to 20-30°C before
reconstitution.
If a gel forms on reconstitution, do not use.

Electrolyte Concentration
Citrate.....Not more than 55 mMol/L
Sodium.....Not more than 200 mMol/L
Chloride.....Not more than 200 mMol/L
Fibrinogen.....Not more than 80% of protein
14-0855-503E
14-0925-502C

POM

FACSIMILE
DON'T USE

**Antihæmophilic
Factor (Human)
Heat-Treated
Dried Factor VIII
Fraction, Heat-Treated
Kofate[®]-HT
Lyophilised Powder**

U.S. License No. 8
Product License No. 0055/0107

Mfd. by **Cutter Biologicals**
Berkeley, CA 94710 USA, Division of
Miles Laboratories, Inc., Elkhart, IN 48514 USA
Dist. by **Cutter** Division of Miles Laboratories, Ltd.
Stoke Court, Stoke Poges, Slough SL2 4LY England

Date removed
from refrigerator _____

For Intravenous Administration Only
Contains No Preservative
Sterile — Nonpyrogenic
To be diluted with 40 ml. Sterile Water for Injection
HEPATITIS DANGER — SEE INSERT LEAFLET
The risk of transmission of hepatitis is present.
Directions For Use: See Insert Leaflet.
Store at 2-8°C. DO NOT FREEZE.
Allow to warm to 20-30°C before
reconstitution.
If a gel forms on reconstitution, do not use.

Electrolyte Concentration
Citrate.....Not more than 55 mMol/L
Sodium.....Not more than 200 mMol/L
Chloride.....Not more than 200 mMol/L
Fibrinogen.....Not more than 80% of protein
14-0855-503E
14-0925-502C

POM